Deals
The pact between Madrigal Pharmaceuticals and Ruzhou Ribo Life Sciences could complement the former’s Rezdiffra, the first FDA-approved therapy for MASH. That drug made $287.3 million in the third quarter of 2025.
FEATURED STORIES
Henry Gosebruch, who has $3.5 billion in capital to deploy, is thinking broad as he steers the decades-old biotech out of years of turmoil.
Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.
Buying vaccine biotech Dynavax was an easy choice for Sanofi despite anti-vaccine moves by the Trump administration.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Vivoryon Therapeutics AG, announced its third quarter business update for the period ending September 30, 2019.
Liminal BioSciences Inc. has announced that it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. (“PBL”) to KKR & Co., a leading global investment firm (“KKR”).
Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, announced that that it has engaged Kilmer Lucas Inc. to provide the Company with select U.S. and Canadian investor relations and strategic advisory services..
Mesoblast Limited reported operational highlights and financial results for the first quarter ended September 30, 2019.
Galapagos NV announces a share capital increase arising from warrant exercises.
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers.
Medexus Pharmaceuticals Inc. announced that it plans to host a conference call at 8:00 AM Eastern Time on Monday, December 2, 2019 to discuss the Company’s financial results for the second quarter ended September 30, 2019, as well as the Company’s corporate progress and other developments.
BioNovelus, Inc. announces the closing of its previously announced acquisition of Corvus Consulting, LLC..
On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.
Patented AltuCaps® for Microencapsulation of stem cells for autoimmune and inflammatory diseases: Partnering opportunities available